Skip to main content

Advertisement

Log in

The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor

  • Clinical Trials
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

This study evaluated the effects of varying degrees of hepatic impairment on the pharmacokinetics and safety of valdecoxib following single and multiple dosing.

Methods

This was an open-label, randomised, parallel group study in 12 subjects with mild hepatic impairment (Child-Pugh Class A) and in 13 with moderate hepatic impairment (Child-Pugh Class B) matched for age, weight, sex, and smoking status; there were two control groups of 12 healthy volunteers, one for each study group. All subjects received a single dose of valdecoxib 20 mg on day 1 and valdecoxib 20 mg twice daily on days 4–7, followed by a single morning dose on day 8. Plasma concentrations of free (unbound) and total valdecoxib and its active hydroxylated metabolite (SC-66905) were measured following single and multiple dosing (day 1 and day 8). Additionally, all subjects received a single intravenous dose of lidocaine 60 mg during the pretreatment period to determine plasma concentrations of monoethylglycinexylidide (MEGX) as a marker of hepatic CYP3A4 activity.

Results

The mean apparent oral clearance of free valdecoxib in plasma at steady state decreased by 22–25% in those with mild to moderate impairment (corresponding to a 28–33% increase in the AUC of free valdecoxib and a 19–23% decrease in the AUC of total SC-66905). The mean free fraction of valdecoxib in plasma increased by 9–38%, resulting in a mean decrease in apparent oral clearance of total valdecoxib in plasma of 0–15% (corresponding to a 0–17% increase in the AUC of total valdecoxib). Individual AUCs for free valdecoxib and total SC-66905 did not correlate well with AUCs for MEGX, indicating that decreases in intrinsic clearance of valdecoxib in those with hepatic impairment could not solely be explained by decreased CYP3A4 expression in hepatic impairment.

Conclusions

In our small study sample, mild and moderate hepatic impairment appeared to have only a modest effect on valdecoxib and SC-66905 pharmacokinetics. The adjustment of valdecoxib dose or dosing regimen does not appear mandatory in subjects with mild or moderate hepatic impairment, although caution is necessary during treatment of these patients with valdecoxib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Final report for an open label, randomized, single dose crossover study to compare the pharmacokinetics and bioavailability of intravenous and oral tablet valdecoxib formulations in healthy adult subjects. GD Searle & Co, Protocol No. N91-99-02-070; Report No. N91-00-06-070, 12 September 2000 [Pharmacia internal report]

  2. Morgan DJ, McLean AJ (1995) Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 29:370–391

    CAS  PubMed  Google Scholar 

  3. Rodighiero V (1999) Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 37:399–431

    CAS  PubMed  Google Scholar 

  4. Thummel KE, Shen DD (2001) Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE (eds) Goodman and Gilmans’ the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 1924–2023

    Google Scholar 

  5. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling (May 2003) Guidance for Industry. Center for Drug Evaluation and Research, Food and Drug Administration

  6. Validation of a liquid chromatographic/tandem mass spectrometric assay for the quantitation of SC-69124, SC-65872 and SC-66905 in human plasma for Pharmacia by CEDRA Corporation (18 March 2002) Document Number: M2001097 [Pharmacia internal report]

  7. The method development and validation of a high performance liquid chromatographic mass spectrometric assay with MS/MS detection for free SC-65872 in human plasma for Searle at Phoenix International Life Sciences Inc (4 August 2000) Document Number: M2099283 [Pharmacia internal report]

  8. The method development and validation of a high performance liquid chromatographic mass spectrometric assay with MS/MS detection for SC-65872, SC-66905 and SC-69124 in human whole blood for Searle at Phoenix International Life Sciences Inc (20 March 1998) Document Number: M2097208 [Pharmacia internal report]

  9. The method development and validation of a high performance liquid chromatographic mass spectrometric assay with MS/MS detection for SC-65872, SC-66905 and SC-69124 in human urine for Searle at Phoenix International Life Sciences Inc (31 January 2000) Document Number: M2099166 [Pharmacia internal report]

  10. George J, Murray M, Byth K, Farrell GC (1995) Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21:120–128

    Article  CAS  PubMed  Google Scholar 

  11. Blaschke TF (1977) Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 2:32–44

    CAS  PubMed  Google Scholar 

  12. Tillement JP, Lhoste F, Giudicelli JF (1978) Diseases and drug protein binding. Clin Pharmacokinet 3:144–154

    CAS  PubMed  Google Scholar 

  13. Rowland MF, Blaschke TF, Meffin PJ, Williams RL (1976) Pharmacokinetics in disease states modifying hepatic and metabolic function. In: Benet (ed) The effect of disease states on drug pharmacokinetics. American Pharmaceutical Association, Washington DC, pp 53–75

  14. Albengres E, Urien S, Kusmierek J, Tillement JP (1982) Benoxaprofen: plasma binding and binding interactions with some drugs and endogenous compounds. Eur J Rheumatol Inflamm 5:87–92

    CAS  PubMed  Google Scholar 

  15. Bergquist C, Lindegard J, Salmonson T (1999) Dosing recommendations in liver disease. Clin Pharmacol Ther 66:201–204

    Article  CAS  PubMed  Google Scholar 

  16. Noveck RJ, McMahon FG, Hubbard R., Karim A (2000) Pharmacokinetic effects of celecoxib, a selective cyclooxygenase 2 inhibitor (COX-2), in alcoholic cirrhosis and healthy subjects. Clin Pharmacol Ther 67:164

    Google Scholar 

  17. Davies NM, McLachlan AJ, Day RO, Williams KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38:225–242

    CAS  PubMed  Google Scholar 

  18. Schwartz JI, Larson PJ, Gertz BJ, Cote J, Lasseter K, Porras AG (2000) Rofecoxib steady-state pharmacokinetics in moderate hepatic insufficiency patients. Am J Gastroenterol 95:2519

    Article  Google Scholar 

  19. Schwartz JI, Larson PJ, Gertz BJ, Cote J, Lasseter K, Porras AG (2001) Steady-state rofecoxib pharmacokinetics in moderate hepatic insufficiency patients. Clin Pharmacol Ther 69:60

    Google Scholar 

  20. Agrawal NGB, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, Larson PJ, Cote J, Dilzer SC, Lasseter KC, Alam I, Petty KJ, Gottesdiener KM (2003) Pharmacokinetics of etoricoxib in patients with hepatic impairment. J Clin Pharmacol 43:1136–1148

    Article  CAS  PubMed  Google Scholar 

  21. Human pharmacokinetics and bioavailability of valdecoxib: summary report of all data and overall conclusions. GD Searle & Co, Report No. N91-00-07-810, December 2000 [Pharmacia internal report]

Download references

Acknowledgements

The procedures in this study complied with the current laws of the country in which they were performed (USA).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nenad Sarapa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarapa, N., Britto, M.R., Mainka, M.B. et al. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor. Eur J Clin Pharmacol 61, 247–256 (2005). https://doi.org/10.1007/s00228-005-0909-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0909-6

Keywords

Navigation